(A) The incidence of OME in the VA group compared to the non-VA group. (B) The rate of tympanostomy tube insertion in the VA group and non-VA group. by Miki Kashiwagi (21439684)

Subjects:

The number, age, and weight of the patients with cleft lip and palate in the velar adhesion VA group and non-VA group. by Miki Kashiwagi (21439684)

Subjects:

The table shows the significant and non-significant altered group with different parameters. by Ashraf Attia Mahmoud (21262201)

Significantly Enriched Pathways. by Jiyong Zhang (2498740)

Subjects:

Mean values and 95% confidence intervals for recovery time, Average NN Interval (AVNN); Standard Deviation of NN Intervals (SDNN), Low Frequency/ High Frequency Ratio (LF/HF); and... by Robert Trybulski (10998702)

Most significant muscle activation values. by María Benito-de-Pedro (22057468)

Subjects:

Degeneration Saline group presented with significant decreased final weight in relation to other groups. by Flavia Gomes Velasque Gama (21175112)

Significant repeated measurements sEMG outcomes. by María Benito-de-Pedro (22057468)

Subjects:

Significant single measurement sEMG outcomes. by María Benito-de-Pedro (22057468)

Subjects:

Nineteen SNPs with significant association (<i>P < </i>5 × 10⁻⁸) with risk on minJSW decrease in knee OA. by Mieke L. M. Bentvelzen (21594442)

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”

Seasonal spatial-temporal trend of NDVI in burned areas across Africa (2001–2020). Percentages (%) of increases or decreases (%) based on the Mann-Kendall test and statistically significant (<i>p</i> < 0.05) and non-significant (p > 0.05) values. by Oswaldo Maillard (20660661)

The cleft width at three timepoints: (A) at the patient’s birth, (B) at cheiloplasty, and (C) at palatoplasty. by Miki Kashiwagi (21439684)

Subjects:

The dental arch length at three timepoints: (A) at the patient’s birth, (B) at cheiloplasty, and (C) at palatoplasty. by Miki Kashiwagi (21439684)

Subjects:

The alveolar width at three timepoints: (A) at the patient’s birth, (B) at cheiloplasty, and (C) at palatoplasty. by Miki Kashiwagi (21439684)

Subjects:

The dental arch width at three timepoints: (A) at the patient’s birth, (B) at cheiloplasty, and (C) at palatoplasty. by Miki Kashiwagi (21439684)

Subjects:

Comparative analysis of macronutrient compositions between baseline and end of intervention (*p < 0.05, ^ns Non-significant results). by Duc Tran Quang (20564967)

Comparative analysis of caloric intake between baseline and end of intervention (*p < 0.05, ^ns Non-significant results). by Duc Tran Quang (20564967)